SiBone (NASDAQ:SIBN) Insider Anshul Maheshwari Sells 11,636 Shares of Stock

Key Points

• SiBone insider Anshul Maheshwari sold 11,636 shares at an average price of $20.11, generating approximately $234,000. The sale reduced his holdings by 4.95% to 223,284 shares, following several other recent sales.
• SiBone shares recently traded at $19.43, down 0.6%, while the company reported a quarterly loss of $0.09 per share—better than the expected $0.15 loss—and revenue of $56.01 million.
• Analysts maintain a generally positive view, with six Buy ratings and one Sell rating, an overall “Moderate Buy” consensus, and an average price target of $24.17. Institutional investors own approximately 98.11% of the company.

SiBone (NASDAQ:SIBN - Get Free Report) insider Anshul Maheshwari sold 11,636 shares of the stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $20.11, for a total transaction of $233,999.96. Following the transaction, the insider owned 223,284 shares in the company, valued at approximately $4,490,241.24. This represents a 4.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Anshul Maheshwari also recently made the following trade(s):

• On Friday, August 21st, Anshul Maheshwari sold 11,228 shares of SiBone stock. The stock was sold at an average price of $20.02, for a total value of $224,784.56.
• On Wednesday, August 19th, Anshul Maheshwari sold 5,747 shares of SiBone stock. The shares were sold at an average price of $19.55, for a total transaction of $112,353.85.
• On Monday, August 17th, Anshul Maheshwari sold 4,665 shares of SiBone stock. The shares were sold at an average price of $18.65, for a total transaction of $87,002.25.
• On Thursday, July 2nd, Anshul Maheshwari sold 3,317 shares of SiBone stock. The stock was sold at an average price of $16.77, for a total transaction of $55,626.09.

SiBone Stock Down 0.6%

SIBN traded down $0.11 during trading on Wednesday, hitting $19.43. The stock had a trading volume of 601,112 shares, compared to its average volume of 544,512. The stock has a 50 day simple moving average of $17.74 and a two-hundred day simple moving average of $15.40. The company has a market capitalization of $861.72 million, a PE ratio of -57.15 and a beta of 0.66. The company has a debt-to-equity ratio of 0.20, a quick ratio of 7.55 and a current ratio of 9.15. SiBone has a twelve month low of $11.48 and a twelve month high of $21.89.

SiBone (NASDAQ:SIBN - Get Free Report) last announced its earnings results on Monday, August 3rd. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.06. The firm had revenue of $56.01 million for the quarter, compared to the consensus estimate of $55.34 million. SiBone had a negative return on equity of 8.23% and a negative net margin of 6.85%. On average, research analysts predict that SiBone will post -0.4 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on SIBN shares. Weiss Ratings raised SiBone from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Thursday, August 20th. Truist Financial reissued a "buy" rating and set a $23.00 price target (up from $21.00) on shares of SiBone in a research report on Tuesday, August 4th. TD Cowen increased their price objective on shares of SiBone from $18.00 to $20.00 and gave the stock a "buy" rating in a research note on Tuesday, August 4th. Finally, UBS Group upped their price target on shares of SiBone from $24.00 to $25.00 and gave the company a "buy" rating in a report on Tuesday, August 4th. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $24.17.

Institutional Investors Weigh In On SiBone

Several institutional investors and hedge funds have recently added to or reduced their stakes in SIBN. California State Teachers Retirement System boosted its holdings in SiBone by 1,751.6% in the 2nd quarter. California State Teachers Retirement System now owns 726,942 shares of the company's stock worth $11,864,000 after buying an additional 687,681 shares during the last quarter. VELA Investment Management LLC lifted its position in shares of SiBone by 7.4% in the second quarter. VELA Investment Management LLC now owns 201,094 shares of the company's stock valued at $3,282,000 after acquiring an additional 13,934 shares in the last quarter. Versant Capital Management Inc lifted its position in shares of SiBone by 102.9% in the second quarter. Versant Capital Management Inc now owns 1,749 shares of the company's stock valued at $29,000 after acquiring an additional 887 shares in the last quarter. Bank of America Corp DE boosted its stake in SiBone by 8.7% during the 1st quarter. Bank of America Corp DE now owns 419,473 shares of the company's stock worth $5,298,000 after purchasing an additional 33,688 shares during the last quarter. Finally, ADAR1 Capital Management LLC acquired a new stake in shares of SiBone in the first quarter valued at about $159,000. Hedge funds and other institutional investors own 98.11% of the company's stock.

SiBone Company Profile

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source